Pulse Biosciences has entered a research partnership with The University of Texas MD Anderson Cancer Center, US, to investigate the nPulse Vybrance Percutaneous Electrode System’s use in treating thyroid cancers.
According to the agreement, researchers at MD Anderson will carry out a clinical trial to evaluate the effectiveness and safety of nPulse technology use in the treatment of papillary thyroid microcarcinoma, a prevalent form of thyroid cancer in the US. The team is spearheaded by head and neck surgery associate professor Victoria Banuchi.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study is scheduled to begin in early 2026 and will be conducted at two centres, enrolling 30 subjects.
Preclinical trials are ongoing under an existing material transfer agreement with MD Anderson researchers.
These studies are focused on assessing the impact of nanosecond pulsed field ablation (nsPFA) energy on anaplastic thyroid carcinoma.
The nPulse Vybrance percutaneous electrode system comprises a percutaneous needle electrode to be used with the company’s nPulse cConsole.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis electrode is tailored to deliver nsPFA energy, which enables nonthermal ablation of cellular tissue while sparing noncellular structures and avoiding thermal necrosis.
The system has secured 510(k) clearance from the US Food and Drug Administration (FDA) for soft tissue ablation in percutaneous and intraoperative procedures, excluding cardiac applications.
Pulse Biosciences CEO and co-chairman Paul LaViolette said: “We believe the nonthermal mechanism of action of nsPFA, which limits scarring, fibrosis, and damage to critical surrounding structures, positions our nPulse technology as potentially the ideal treatment for benign and malignant thyroid tumours.
“We look forward to carrying this collaborative work forward to evaluate how our game-changing technology may benefit these patients.”
In September 2025, Pulse Biosciences obtained FDA approval for its investigational device exemption (IDE) to initiate a study of its nsPFA cardiac surgery system to treat atrial fibrillation.
